In December 2003, Biorelaince was acquired by Invitrogen, itself formerly quite extensively SBIR involved. BioReliance Corporation had provided contract services organization in testing and development and manufacturing for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. Through its testing and development business segment, the Company evaluated products to ensure that they were free of disease-causing agents or do not cause adverse effects, characterizes products' chemical structures, develops formulations for long-term stability and validates purification processes under regulatory guidelines. In it manufacturing business segment, BioReliance developed production processes and manufactured biologics on behalf of clients, both for use in clinical trials and for the worldwide commercial market.
